文献速递免疫规划卫生政策与健康促进

单剂HPV疫苗接种后抗体应答的血清学检测方法评估

Evaluation of serological assays to monitor antibody responses to single-dose HPV vaccines.
PubMed 文献 · Vaccine · 2020-07-24

本研究评估了七种血清学检测方法在530份接种不同剂次Cervarix或Gardasil疫苗后36个月内的血清样本中检测HPV-16/18免疫应答的能力。结果显示现有血清学检测方法可用于监测单剂HPV疫苗接种后的抗体应答,但HPV-18的血清阳性率和检测一致性低于HPV-16。

要点

  • 现有血清学检测方法可用于监测单剂HPV疫苗接种后的抗体应答。
  • HPV-16血清阳性率单剂为97.1-99.5%,总体为98.8-99.8%。
  • HPV-18血清阳性率单剂为63.9-94.7%,总体为86.2-97.9%。

核心结论

  • 现有血清学检测方法可用于监测单剂HPV疫苗接种后的抗体应答。

研究设计与样本

  • 评估七种检测方法在530份接种不同剂次Cervarix或Gardasil疫苗后36个月内的血清样本中的表现。

主要发现

  • HPV-16血清阳性率单剂为97.1-99.5%,总体为98.8-99.8%。
  • HPV-18血清阳性率单剂为63.9-94.7%,总体为86.2-97.9%。
  • HPV-16与SEAP-NA的相关系数单剂为0.43-0.85,总体为0.51-0.90。
  • HPV-18与SEAP-NA的相关系数单剂为0.31-0.99,总体为0.27-0.96。
  • HPV-18血清阴性率范围为5.5-17.3%,LIA-4和GST-L1的血清阴性比例>10%,最强相关因素为单剂接种和接种Gardasil。

关键数值与推荐

  • HPV-16血清阴性率所有检测均<5%。
  • HPV-16的CV范围单剂为4.0-18.0%,总体为2.9-19.5%。
  • HPV-18的CV范围单剂为8.1-18.2%,总体为4.6-18.6%。
  • HPV-16的ICC范围单剂为0.77-0.99,总体为0.74-0.99。
  • HPV-18的ICC范围单剂为0.75-0.99,总体为0.83-0.99。

临床怎么用

  • 在监测单剂HPV疫苗接种后的抗体应答时,可选用现有血清学检测方法。
  • 对于HPV-18,需注意不同检测方法血清阳性率和一致性存在差异。

局限性

  • 未评估其他HPV型别。
  • 样本来源限于接种Cervarix或Gardasil的参与者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Whether existing serological assays are sufficiently robust to measure the lower antibody levels expected following single-dose HPV vaccination is unknown. METHODS: We evaluated seven assays measuring HPV-16/18 immunological responses overall and by number of doses in 530 serum samples from participants receiving varying doses of Cervarix or Gardasil up to 36-months post-vaccination. Serum was evaluated by simplex (HPV-16 ELISA, HPV-18 ELISA), multiplex (LIA-4, VLP-MIA, M9ELISA, GST-L1), and high-throughput pseudovirion-based neutralization assays (HT-PBNA), and results were compared to the gold standard HPV-16/18 secreted alkaline phosphatase neutralization assay (SEAP-NA). Reproducibility was assessed by the coefficient of variation (CV) and intraclass correlation coefficient (ICC). Percent agreement, Pearson correlation, and weighted-kappa were used to assess validity. Determinants of seronegativity were evaluated by chi-squared test. RESULTS: HPV-16: Seropositivity range was 97.1-99.5% for single dose and 98.8-99.8% overall. CV range was 4.0-18.0% for single dose and 2.9-19.5% overall. ICC range was 0.77-0.99 for single dose and 0.74-0.99 overall. Correlation with SEAP-NA range was 0.43-0.85 for single dose and 0.51-0.90 overall. Weighted-kappa range was 0.34-0.82 for single dose and 0.45-0.84 overall. HPV-18: Seropositivity range was 63.9-94.7% for single dose and 86.2-97.9% overall. CV range was 8.1-18.2% for single dose and 4.6-18.6% overall. ICC range was 0.75-0.99 for single dose and 0.83-0.99 overall. Correlation with SEAP-NA range was 0.31-0.99 for single dose and 0.27-0.96 overall. Weighted-kappa range was 0.35-0.83 for single dose and 0.45-0.84 overall. HPV-16 seronegativity was <5% for all assays. HPV-18 seronegativity range was 5.5-17.3%. For LIA-4 and GST-L1 where the proportion of seronegativity was >10%, the strongest correlates of seronegativity were receiving a single vaccine dose and receiving Gardasil. CONCLUSIONS: These results support the utility of existing serological assays to monitor antibody responses following single-dose HPV vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Tsang SH, Basu P, Bender N, et al. Evaluation of serological assays to monitor antibody responses to single-dose HPV vaccines. Vaccine. 2020. PMID: 32713678. doi:10.1016/j.vaccine.2020.07.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。